The Search for RNAs

Premium

The creation of new drugs is a vital part of the health-care system. Researchers in academia and in industry are always searching for new ways to combat disease — more efficiently, with fewer toxicities, and less chance of rejection. Until recently, most medicines have been limited to the classic formulation of a small molecule targeting a protein to disrupt its function. But there are many targets and formulations that have yet to be fully exploited, particularly those involving RNAs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.